Contineum Therapeutics (NASDAQ:CTNM) Receives New Coverage from Analysts at Robert W. Baird

Robert W. Baird started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a research report released on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $32.00 price objective on the stock.

Separately, Royal Bank of Canada boosted their price objective on shares of Contineum Therapeutics from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, August 14th.

Contineum Therapeutics Trading Up 1.3 %

CTNM opened at $16.28 on Tuesday. The firm has a 50-day moving average price of $18.00 and a 200-day moving average price of $17.65. Contineum Therapeutics has a twelve month low of $13.27 and a twelve month high of $22.00.

Contineum Therapeutics (NASDAQ:CTNM) last posted its earnings results on Tuesday, August 13th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.02). Equities research analysts anticipate that Contineum Therapeutics will post -2.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Contineum Therapeutics

Hedge funds have recently bought and sold shares of the company. Sandia Investment Management LP purchased a new position in Contineum Therapeutics during the second quarter valued at approximately $88,000. Rhumbline Advisers bought a new stake in Contineum Therapeutics during the second quarter valued at approximately $118,000. Bank of New York Mellon Corp bought a new stake in Contineum Therapeutics during the second quarter valued at approximately $356,000. Driehaus Capital Management LLC bought a new stake in Contineum Therapeutics during the second quarter valued at approximately $1,174,000. Finally, Squarepoint Ops LLC bought a new stake in Contineum Therapeutics during the second quarter valued at approximately $2,642,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).